Review Article

Serum Biomarkers for Traumatic Brain Injury

Authors: Miriam D. Neher, MD, Chesleigh N. Keene, MA, Megan C. Rich, BA, Hunter B. Moore, MD, Philip F. Stahel, MD

Abstract

There is a lack of reliable serum biomarkers for routine use in the diagnostic workup of people with traumatic brain injury. Multiple biomediators and biomarkers have been described in the pertinent literature in recent years; however, only a few candidate molecules have been associated with high sensitivity and high specificity for risk stratification and outcome prediction after traumatic brain injury. This review was designed to provide an overview of the state of the art regarding established serum biomarkers in the field and to outline future directions of investigation.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Corrigan JD, Selassie AW, Orman JA. The epidemiology of traumatic brain injury. J Head Trauma Rehabil 2010;25:72-80.
 
2. Roozenbeek B, Maas AI, Menon DK. Changing patterns in the epidemiology of traumatic brain injury.Nat Rev Neurol 2013;9:231-236.
 
3. Stahel PF, Flierl MA. Closed head injury, in Smith WR, Stahel PF (eds): Management of Musculoskeletal Injuries in the Trauma Patient. New York, Springer, 2014:297-304.
 
4. Bryan CJ, Clemans TA. Repetitive traumatic brain injury, psychological symptoms, and suicide risk in a clinical sample of deployed military personnel. JAMA Psychiatry 2013;70:686-691.
 
5. Mac Donald CL, Johnson AM, Cooper D, et al. Detection of blast-related traumatic brain injury in U.S. military personnel. N Engl J Med 2011; 364:2091-2100.
 
6. Wall PL. Posttraumatic stress disorder and traumatic brain injury in current military populations: a critical analysis. J Am Psychiatr Nurses Assoc 2012;18:278-298.
 
7. DeKosky ST, Blennow K, Ikonomovic MD, et al. Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol 2013;9:192-200.
 
8. Ingebrigtsen T, Romner B. Biochemical serum markers of traumatic brain injury. J Trauma 2002;52:798-808.
 
9. Berger RP. The use of serum biomarkers to predict outcome after traumatic brain injury in adults and children. J Head Trauma Rehabil 2006;21:315-333.
 
10. Prieto DA, Ye X, Veenstra TD. Proteomic analysis of traumatic brain injury: the search for biomarkers. Expert Rev Proteomics 2008;5:283-291.
 
11. Hayes RL, Robinson G, Muller U, et al. Translation of neurological biomarkers to clinically relevant platforms. Methods Mol Biol 2009; 566:303-313.
 
12. Shoemaker LD, Achrol AS, Sethu P, et al. Clinical neuroproteomics and biomarkers: from basic research to clinical decision making.Neurosurgery 2012;70:518-525.
 
13. Mondello S, Muller U, Jeromin A, et al. Blood-based diagnostics of traumatic brain injuries. Expert Rev Mol Diagn 2011;11:65-78.
 
14. Bakay RA, Ward AA Jr. Enzymatic changes in serum and cerebrospinal fluid in neurological injury. J Neurosurg 1983;58:27-37.
 
15. Kochanek PM, Berger RP, Fink EL, et al. The potential for bio-mediators and biomarkers in pediatric traumatic brain injury and neurocritical care. Front Neurol 2013;4:1-9.
 
16. Plebani M. Lessons from controversy: biomarkers evaluation. Clin Chem Lab Med 2013;51:247-248.
 
17. Daoud H, Alharfi I, Alhelali I, et al. Brain injury biomarkers as outcome predictors in pediatric severe traumatic brain injury. Neurocrit Care 2013 August 13 [Epub ahead of print] .
 
18. Begaz T, Kyriacou DN, Segal J, et al. Serum biochemical markers for post-concussion syndrome in patients with mild traumatic brain injury. J Neurotrauma 2006;23:1201-1210.
 
19. Bakay RA, Sweeney KM, Wood JH. Pathophysiology of cerebrospinal fluid in head injury: part 2. Biochemical markers for central nervous system trauma. Neurosurgery 1986;18:376-382.
 
20. Zetterberg H, Smith DH, Blennow K. Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol 2013;9:201-210.
 
21. Flierl MA, Guadiani JL, Sabel AL, et al. Complement C3 serum levels in anorexia nervosa: a potential biomarker for the severity of disease? Ann Gen Psychiatry 2011;10:16.
 
22. Zhao P, Gao S, Lin B. Elevated levels of serum S100B is associated with the presence and outcome of haemorrhagic shock. Clin Lab 2012; 58:1051-1055.
 
23. Lee SJ, Kim CW, Lee KJ, et al. Elevated serum S100B levels in acute spinal fracture without head injury. Emerg Med J 2010;27:209-212.
 
24. Glassberg E, Lipsky AM, Lending G, et al. Blood glucose levels as an adjunct for prehospital field triage. Am J Emerg Med 2013;31:556-561.
 
25. Lescot T, Boroli F, Reina V, et al. Effect of continuous cerebrospinal fluid drainage on therapeutic intensity in severe traumatic brain injury. Neurochirurgie 2012;58:235-240.
 
26. Stahel PF, Smith WR. Closed head injury, in Bland KI, Sarr MG, Bu¨chler MW, et al, (eds): Trauma Surgery-Handbooks in General Surgery. London, Springer-Verlag, 2011, pp 83-101.
 
27. McAleese SM, Dunbar B, Fothergill JE, et al. Complete amino acid sequence of the neurone-specific gamma isozyme of enolase (NSE) from human brain and comparison with the non-neuronal alpha form (NNE). Eur J Biochem 1988;178:413-417.
 
28. Costine BA, Quebeda-Clerkin PB, Dodge CP, et al. Neuron-specific enolase, but not S100B or myelin basic protein, increases in peripheral blood corresponding to lesion volume after cortical impact in piglets. J Neurotrauma 2012;29:2689-2695.
 
29. Giacoppo S, Bramanti P, Barresi M, et al. Predictive biomarkers of recovery in traumatic brain injury. Neurocrit Care 2012;16:470-477.
 
30. Nygaard O, Langbakk B, Romner O. Neuron-specific enolase concentrations in serum and cerebrospinal fluid in patients with no previous history of neurological disorder. Scand J Clin Lab Invest 1998;58:183-186.
 
31. Chabok SY, Moghadam AD, Saneei Z, et al. Neuron-specific enolase and S100BB as outcome predictors in severe diffuse axonal injury. J Trauma Acute Care Surg 2012;72:1654-1657.
 
32. Topolovec-Vranic J, Pollmann-Mudryj MA, Ouchterlony D, et al. The value of serum biomarkers in prediction models of outcome after mild traumatic brain injury. J Trauma 2011;71:S478-S486.
 
33. Meric E, Gunduz A, Turedi S, et al. The prognostic value of neuron-specific enolase in head trauma patients. J Emerg Med 2010;38:297-301.
 
34. Woertgen C, Rothoerl RD, Brawanski A. Neuron-specific enolase serum levels after controlled cortical impact injury in the rat. J Neurotrauma 2001;18:569-573.
 
35. Guzel A, Er U, Tatli M, et al. Serum neuron-specific enolase as a predictor of short-term outcome and its correlation with Glasgow Coma Scale in traumatic brain injury. Neurosurg Rev 2008;31:439-444.
 
36. Herrmann M, Jost S, Kutz S, et al. Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography. J Neurotrauma 2000;17:113-122.
 
37. Naeimi ZS, Weinhofer A, Sarahrudi K, et al. Predictive value of S-100B protein and neuron specific-enolase as markers of traumatic brain damage in clinical use. Brain Inj 2006;20:463-468.
 
38. Vos PE, Lamers KJ, Hendriks JC, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 2004;62:1303-1310.
 
39. Zurek J, Fedora M. The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury. Acta Neurochir (Wien) 2012;154:93-103.
 
40. Gradisek P, Osredkar J, Korsic M, et al. Multiple indicators model of long-term mortality in traumatic brain injury. Brain Inj 2012;26:1472-1481.
 
41. Olivecrona M, Rodling-Wahlstrom M, Naredi S, et al. S-100B and neuron specific enolase are poor outcome predictors in severe traumatic brain injury treated by an intracranial pressure targeted therapy. J Neurol Neurosurg Psychiatry 2009;80:1241-1247.
 
42. Ingebrigtsen T, Romner B. Biochemical serum markers for brain damage: a short review with emphasis on clinical utility in mild head injury. Restor Neurol Neurosci 2003;21:171-176.
 
43. de Kruijk JR, Leffers P, Menheere PP, et al. S-100B and neuron-specific enolase in serum of mild traumatic brain injury patients. A comparison with health controls. Acta Neurol Scand 2001;103:175-179.
 
44. Johnsson P, Blomquist S, Luhrs C, et al. Neuron-specific enolase increases in plasma during and immediately after extracorporeal circulation. Ann Thorac Surg 2000;69:750-754.
 
45. Pelinka LE, Jafarmadar M, Redl H, et al. Neuron-specific-enolase is increased in plasma after hemorrhagic shock and after bilateral femur fracture without traumatic brain injury in the rat. Shock 2004;22:88-91.
 
46. Pelinka LE, Hertz H, Mauritz W, et al. Nonspecific increase of systemic neuron-specific enolase after trauma: clinical and experimental findings. Shock 2005;24:119-123.
 
47. Franjevic A, Pavicevic R, Bubanovic G. Differences in initial NSE levels in malignant and benign diseases of the thoracic wall. Clin Lab 2012; 58:245-252.
 
48. Astrand R, Unden J, Romner B. Clinical use of the calcium-binding S100B protein. Methods Mol Biol 2013;963:373-384.
 
49. Kovesdi E, Luckl J, Bukovics P, et al. Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics. Acta Neurochir (Wien) 2010;152:1-17.
 
50. Zongo D, Ribereau-Gayon R, Masson F, et al. S100-B protein as a screening tool for the early assessment of minor head injury. Ann Emerg Med 2012;59:209-218.
 
51. Egea-Guerrero JJ, Revuelto-Rey J, Murillo-Cabezas F, et al. Accuracy of the S100beta protein as a marker of brain damage in traumatic brain injury. Brain Inj 2012;26:76-82.
 
52. Stranjalis G, Korfias S, Papapetrou C, et al. Elevated serum S-100B protein as a predictor of failure to short-term return to work or activities after mild head injury. J Neurotrauma 2004;21:1070-1075.
 
53. Goyal A, Carter M, Niyonkuru C, et al. S100b as a prognostic biomarker in outcome prediction for patients with severe TBI. J Neurotrauma 2013;30:946-957.
 
54. Kleindienst A, Ross Bullock M. A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma 2006; 23:1185-1200.
 
55. Goncalves CA, Leite MC, Guerra MC. Adipocytes as an important source of serum S100B and possible roles of this protein in adipose tissue. Cardiovasc Psychiatry Neurol 2010;2010:790431.
 
56. Gelse K, Ekici AB, Cipa F, et al. Molecular differentiation between osteophytic and articular cartilage-clues for a transient and permanent chondrocyte phenotype. Osteoarthritis Cartilage 2012;20:162-171.
 
57. Torabian S, Kashani-Sabet M. Biomarkers for melanoma. Curr Opin Oncol 2005;17:167-171.
 
58. Chan RW, Graham CA, Rainer TH, et al. Use of bone marrow transplantation model system to demonstrate the hematopoietic origin of plasma S100B mRNA. Clin Chem 2007;53:1874-1876.
 
59. Graham CA, Rainer TH. Utility of S100B in head injury care. Ann Emerg Med 2013;61:120-121.
 
60. Dash PK, Zhao J, Hergenroeder G, et al. Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics 2010;7:100-114.
 
61. Jonsson H, Johnsson P, Hoglund P, et al. Elimination of S100B and renal function after cardiac surgery. J Cardiothorac Vasc Anesth 2000; 14:698-701.
 
62. Thelin EP, Johannesson LK, Nelson DW, et al. S100B is an important outcome predictor in traumatic brain injury. J Neurotrauma 2013; 30:519-528.
 
63. Unden J, Astrand R, Waterloo K, et al. Clinical significance of serum S100B levels in neurointensive care. Neurocrit Care 2007;6:94-99.
 
64. Yates D. Traumatic brain injury: serum levels of GFAP and S100B predict outcomes in TBI. Nat Rev Neurol 2011;7:63.
 
65. Korfias S, Stranjalis G, Boviatsis E, et al. Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med 2007;33:255-260.
 
66. Cervellin G, Benatti M, Carbucicchio A, et al. Serum levels of protein S100B predict intracranial lesions in mild head injury. Clin Biochem 2012;45:408-411.
 
67. Rodriguez-Rodriguez A, Egea-Guerrero JJ, Leon-Justel A, et al. Role of S100B protein in urine and serum as an early predictor of mortality after severe traumatic brain injury in adults. Clin Chim Acta 2012; 414:228-233.
 
68. Gonzalez-Mao MC, Reparaz-Andrade A, Del Campo-Perez V, et al. Model predicting survival/exitus after traumatic brain injury: biomarker S100B 24h. Clin Lab 2011;57:587-597.
 
69. Savola O, Hillbom M. Early predictors of post-concussion symptoms in patients with mild head injury. Eur J Neurol 2003;10:175-181.
 
70. Calcagnile O, Unden L, Unden J. Clinical validation of S100B use in management of mild head injury. BMC Emerg Med 2012;12:13.
 
71. Unden J, Romner B. Can low serum levels of S100B predict normal CT findings after minor head injury in adults? An evidence-based review and meta-analysis. J Head Trauma Rehabil 2010;25:228-240.
 
72. Breena RT. Biomarkers revisited: study design, validity and STARD. Will S100-B impact computed tomography use in head injury patients? Ann Emerg Med 2012;59:221-222.
 
73. Muller K, Townend W, Biasca N, et al. S100B serum level predicts computed tomography findings after minor head injury. J Trauma 2007;62:1452-1456.
 
74. Schriger DL, Newman DH. Medical decisionmaking: let’s not forget the physician. Ann Emerg Med 2012;59:219-220.
 
75. Michetti F, Corvino V, Geloso MC, et al. The S100B protein in biological fluids: more than a lifelong biomarker of brain distress. J Neurochem 2012;120:644-659.
 
76. Anderson RE, Hansson LO, Nilsson O, et al. High serum S100B levels for trauma patients without head injuries.Neurosurgery 2001;48:1255-1258.
 
77. Dietrich MO, Tort AB, Schaf DV, et al. Increase in serum S100B protein level after a swimming race. Can J Appl Physiol 2003;28:710-716.
 
78. Stalnacke BM, Ohlsson A, Tegner Y, et al. Serum concentrations of two biochemical markers of brain tissue damage S-100B and neurone specific enolase are increased in elite female soccer players after a competitive game. Br J Sports Med 2006;40:313-316.
 
79. Otto M, Holthusen S, Bahn E, et al. Boxing and running lead to a rise in serum levels of S-100B protein. Int J Sports Med 2000;21:551-555.
 
80. Metting Z, Wilczak N, Rodiger LA, et al. GFAP and S100B in the acute phase of mild traumatic brain injury. Neurology 2012;78:1428-1433.
 
81. Kapural M, Krizanac-Bengez L, Barnett G, et al. Serum S-100beta as a possible marker of blood-brain barrier disruption. Brain Res 2002;940:102-104.
 
82. Piazza O, Storti MP, Cotena S, et al. S100B is not a reliable prognostic index in paediatric TBI. Pediatr Neurosurg 2007;43:258-264.
 
83. Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969Y2000). Neurochem Res 2000;25:1439-1451.
 
84. Schiff L, Hadker N, Weiser S, et al. A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury. Mol Diagn Ther 2012;16:79-92.
 
85. Nylen K, Ost M, Csajbok LZ, et al. Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci 2006;240:85-91.
 
86. Lumpkins KM, Bochicchio GV, Keledjian K, et al. Glial fibrillary acidic protein is highly correlated with brain injury. J Trauma2008;65:778-782.
 
87. Papa L, Lewis LM, Falk JL, et al. Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med 2012;59:471-483.
 
88. Honda M, Tsuruta R, Kaneko T, et al. Serum glial fibrillary acidic protein is a highly specific biomarker for traumatic brain injury in humans compared with S-100B and neuron-specific enolase. J Trauma 2010;69:104-109.
 
89. Pelinka LE, Kroepfl A, Schmidhammer R, et al. Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma 2004;57:1006-1012.
 
90. Vos PE, Jacobs B, Andriessen TM, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 2010;75:1786-1793.
 
91. Diaz-Arrastia R, Wang KK, Papa L, et al. Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein (GFAP). J Neurotrauma 2014;31:19-25.
 
92. Day IN, Thompson RJ. UCHL1 (PGP 9.5): neuronal biomarker and ubiquitin system protein. Prog Neurobiol 2010;90:327-362.
 
93. Yokobori S, Hosein K, Burks S, et al. Biomarkers for the clinical differential diagnosis in traumatic brain injury-a systematic review. CNS Neurosci Ther 2013;19:556-565.
 
94. Papa L, Akinyi L, Liu MC, et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 2010;38:138-144.
 
95. Papa L, Lewis LM, Silvestri S, et al. Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention. J Trauma Acute Care Surg 2012;72:1335-1344.
 
96. Brophy GM, Mondello S, Papa L, et al. Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J Neurotrauma 2011;28:861-870.
 
97. Mondello S, Linnet A, Buki A, et al. Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury. Neurosurgery 2012;70:666-675.
 
98. Tsitsopoulos PP, Marklund N. Amyloid-A peptides and tau protein as biomarkers in cerebrospinal and interstitial fluid following traumatic brain injury: a review of experimental and clinical studies. Front Neurol 2013;4:79.
 
99. Park SY, Tournell C, Sinjoanu RC, et al. Caspase-3- and calpain-mediated tau cleavage are differentially prevented by estrogen and testosterone in beta amyloid-treated hippocampal neurons. Neuroscience 2007;144:119-127.
 
100. Neselius S, Zetterberg H, Blennow K, et al. Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. Brain Inj 2013;27:425-433.
 
101. Ost M, Nylen K, Csajbok L, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 2006;67:1600-1604.
 
102. Zemlan FP, Jauch EC, Mulchahey JJ, et al. C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome.Brain Res 2002;947:131-139.
 
103. Liliang PC, Liang CL, Weng HC, et al. Tau proteins in serum predict outcome after severe traumatic brain injury. J Surg Res 2010;160:302-307.
 
104. Bazarian JJ, Zemlan FP, Mookerjee S, et al. Serum S-100B and cleaved-tau are poor predictors of long-term outcome after mild traumatic brain injury. Brain Inj 2006;20:759-765.
 
105. Bulut M, Koksal O, Dogan S, et al. Tau protein as a serum marker of brain damage in mild traumatic brain injury: preliminary results. Adv Ther 2006;23:12-22.
 
106. Kavalci C, Pekdemir M, Durukan P, et al. The value of serum tau protein for the diagnosis of intracranial injury in minor head trauma. Am J Emerg Med 2007;25:391-395.
 
107. Gyorgy A, Ling G, Wingo D, et al. Time-dependent changes in serum biomarker levels after blast traumatic brain injury. J Neurotrauma 2011;28:1121-1126.
 
108. Su E, Bell MJ, Kochanek PM, et al. Increased CSF concentrations of myelin basic protein after TBI in infants and children: absence of significant effect of therapeutic hypothermia. Neurocrit Care 2012;17:401-407.
 
109. Berger RP, Adelson PD, Pierce MC, et al. Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg 2005;103:61-68.
 
110. Korfias S, Papadimitriou A, Stranjalis G, et al. Serum biochemical markers of brain injury. Mini Rev Med Chem 2009;9:227-234.
 
111. Schmidt OI, Heyde CE, Ertel W, Stahel PF. Closed head injury-an inflammatory disease? Brain Res Rev 2005;48:388-399.
 
112. Woodcock T, Morganti-Kossmann MC. The role of markers of inflammation in traumatic brain injury. Front Neurol 2013;4:18.
 
113. Helmy A, Carpenter KL, Menon DK, et al. The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production. J Cereb Blood Flow Metab 2011;31:658-670.
 
114. Is M, Coskun A, Sanus GZ, et al. High-sensitivity C-reactive protein levels in cerebrospinal fluid and serum in severe head injury: relationship to tumor necrosis factor-alpha and interleukin-6. J Clin Neurosci 2007;14:1163-1171.
 
115. Stahel PF, Morganti-Kossmann MC, Perez D, et al. Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood- brain barrier dysfunction in patients with traumatic brain injury. J Neurotrauma 2001;18:773-781.
 
116. Kossmann T, Stahel PF, Morganti-Kossmann MC, et al. Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury. J Neuroimmunol 1997;73:63-69.
 
117. Bellander BM, Olafsson IH, Ghatan PH, et al. Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B. Acta Neurochir (Wien) 2011;153:90-100.
 
118. Stein DM, Lindel AL, Murdock KR, et al. Use of serum biomarkers to predict secondary insults following severe traumatic brain injury. Shock 2012;37:563-568.
 
119. Hergenroeder GW, Moore AN, McCoy JP Jr, et al. Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury. J Neuroinflammation 2010;7:19.
 
120. Sogut O, Guloglu C, Orak M, et al. Trauma scores and neuron-specific enolase, cytokine and C-reactive protein levels as predictors of mortality in patients with blunt head trauma. J Int Med Res 2010;38:1708-1720.
 
121. Kalabalikis P, Papazoglou K, Gouriotis D, et al. Correlation between serum IL-6 and CRP levels and severity of head injury in children. Intensive Care Med 1999;25:288-292.
 
122. Kossmann T, Stahel PF, Lenzlinger PM, et al. Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with blood-brain barrier dysfunction and nerve growth factor production. J Cereb Blood Flow Metab 1997;17:280-289.
 
123. Kossmann T, Hans VH, Imhof HG, et al. Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock 1995;4:311-317.
 
124. Niyonkuru C, Wagner AK, Ozawa H, et al. Group-based trajectory analysis applications for prognostic biomarker model development in severe TBI: a practical example. J Neurotrauma 2013;30:938-945.
 
125. Berger RP, Bazaco MC, Wagner AK, et al. Trajectory analysis of serum biomarker concentrations facilitates outcome prediction after pediatric traumatic and hypoxemic brain injury. Dev Neurosci 2010;32:396-405.